A Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels
NCT ID: NCT03175757
Last Updated: 2018-09-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
33 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-05-12
Study Completion Date
2018-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess the effects of a turmeric and black cumin seed formulation on cholesterol levels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
NCT02998918
Inflammation
Atherosclerosis
Cardiovascular Disease
COMPLETED
NA
Effect of a Food Supplementation With a Combined Food Supplement on Lipid Pattern, Indexes of Non-alcoholic Fatty Liver Disease and Systemic Inflammation
NCT06247137
Hypercholesterolemia
COMPLETED
NA
A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Forumulation to a Comparator Curcumin Product
NCT02474953
Healthy
COMPLETED
PHASE1
A Comparative Pharmacokinetic Study to Evaluate the Ability of a New Formulation to Enhance Curcuminoids Bioavailability
NCT03621865
Healthy
COMPLETED
NA
Determination of Pharmacokinetics of Different Curcuminoids Preparations: Pilot Study
NCT05542394
Plasma Levels of Different Curcuminoids Preparations
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is a randomized, single-blind, placebo-controlled study to evaluate the effects of a turmeric and black cumin seed formulation on cholesterol levels. Each subject will receive a specific dose of the formulation or placebo twice daily. Participants will undergo assessments of blood tests, vital signs, body weight, waist circumference, hip circumference and waist-to-hip ratio with completion of a questionnaire.
The primary objective of the study is to assess the effects of the turmeric and black cumin seed formulation on fasting levels of Total Cholesterol.
Secondary objectives include assessment of the effects of turmeric and black cumin seed formulation on: fasting levels of: LDL Cholesterol, parameters in the NMR LipoProfile®, Oxidized LDL, Triglycerides, HDL cholesterol, C-reactive protein, blood glucose, Insulin and Hemoglobin A1c, as well as the assessments of the values/scores of body weight, waist circumference, hip circumference, waist-to-hip ratio, blood pressure and the SF-36 survey scores.
The primary objective of the study is to assess the effects of the turmeric and black cumin seed formulation on fasting levels of Total Cholesterol.
Secondary objectives include assessment of the effects of turmeric and black cumin seed formulation on: fasting levels of: LDL Cholesterol, parameters in the NMR LipoProfile®, Oxidized LDL, Triglycerides, HDL cholesterol, C-reactive protein, blood glucose, Insulin and Hemoglobin A1c, as well as the assessments of the values/scores of body weight, waist circumference, hip circumference, waist-to-hip ratio, blood pressure and the SF-36 survey scores.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cholesterol Health
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cholesterol Health Formulation
Turmeric and black cumin seed preparation
Group Type
EXPERIMENTAL
Turmeric and Black Cumin Seed
Intervention Type
DIETARY_SUPPLEMENT
Turmeric and Black Cumin Seed formulation
Placebo
Placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Turmeric and Black Cumin Seed
Turmeric and Black Cumin Seed formulation
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Ambulatory, male or female, between 40 and 75 years of age
2. Meeting one of the following two criteria:
1. Having a BMI between 25.0 and 34.9
2. Waist circumference \> 40.0 inches in males and \> 35.0 inches in females
3. Having Total Cholesterol levels at Baseline/screening of between 190 and 239 mg/dl
4. Generally healthy and having no difficulty with digestion or absorption of food
5. Willing and able to give written informed consent
6. Clearly understands the procedures and requirements for the study
7. Able to maintain stable physical activity and dietary habits throughout the study
8. Willing and able to comply with all study procedures and data recording obligations
9. Having the capability of communicating, including reading in English
2. Meeting one of the following two criteria:
1. Having a BMI between 25.0 and 34.9
2. Waist circumference \> 40.0 inches in males and \> 35.0 inches in females
3. Having Total Cholesterol levels at Baseline/screening of between 190 and 239 mg/dl
4. Generally healthy and having no difficulty with digestion or absorption of food
5. Willing and able to give written informed consent
6. Clearly understands the procedures and requirements for the study
7. Able to maintain stable physical activity and dietary habits throughout the study
8. Willing and able to comply with all study procedures and data recording obligations
9. Having the capability of communicating, including reading in English
Exclusion Criteria
1. Having smoked any cigarette, electronic cigarette, cigar, pipe, or recreational drug in the past 30 days
2. History of allergy or sensitivity to any component of the study products
3. Donation of blood within 30 days prior Baseline/screening
4. Participation in another study within 30 days prior to Baseline/screening
5. Being pregnant, planning on becoming pregnant during study participation or breast feeding
6. Having the following medical condition(s): diabetes, hypotension, hypertension (changed antihypertensive medication or dose in the preceding 3 months and/or likely to do so during the study), cardiovascular disease (arrhythmia, edema with or without congestive heart failure, heart attack, stroke, abnormal EKG), gastrointestinal disease requiring daily prescribed medication (gastroesophageal reflux, gastritis, and peptic or duodenal ulcer), gallbladder disease or gallstones, biliary obstruction (past or present), endocrine disease (hyper- or hypothyroidism), psychiatric disorder (anxiety if untreated, eating disorder) neurologic disease (Parkinson's disease, intracranial hemorrhage, head injury, brain tumor, evidence of delirium, confusion, dementia, Alzheimer's disease, migraine headache (if last migraine headache was \< 3 years prior to Baseline/screening), urologic disease, chronic inflammatory or autoimmune disease, cancer (unless skin cancer other than melanoma which has been treated \> 3 years prior to Baseline/screening), liver and kidney disease, insomnia, blood coagulation disorder (anemia, thrombus, embolism), sleep apnea, or other condition(s) that would preclude participation in the study in the judgment of the investigator/sub-investigator (Sub-I).
7. Currently taking or having taken cholesterol-lowering medication(s) including HMGCR inhibitors, cholesterol binding resins, fibrates, or nicotinic acid \>1 gram/day within 30 days prior to screening
8. Currently taking or having taken a supplemental product that may affect cholesterol levels (red yeast rice, red mold dioscorea, guggulipid, policosanol, pantethine, beta-sitosterol, artichoke leaf, or supplemental fiber) within 30 days prior to Baseline/screening
9. Currently taking or having taken a fish oil or krill oil product within 30 days prior to Baseline/screening
10. Currently taking or having taken anxiolytics and sedative hypnotics, anticonvulsants, antineoplastics, anti-migraine medication(s), opioid analgesics, monoamine oxidase inhibitors (MAOIs), phosphodiesterase inhibitors, adenosine reuptake inhibitors, dopamine agonists, dopamine antagonists, or immunosuppressants within 30 days prior to Baseline/screening
11. Currently talking or having taken anti-inflammatory medication(s) within 14 days prior to screening (unless on a stable daily dose of aspirin 81mg for 3 months prior to screening and not likely to change dose during the study) or in the judgment of the PI/Sub-I would not preclude participation in the study
12. Having had a surgical procedure, pacemaker or any internal medical device other than artificial joints which, in the judgment of the PI/Sub-I, would preclude participation in the study
13. Having had a routine dental cleaning or other dental procedure within 14 days prior to Baseline/screening
14. Having screening laboratory test values: bilirubin \> 2.5 x ULN, AST/SGOT and ALT/SGPT \> 2.5 x ULN, serum creatinine \> 1.5 mg/dL, blood glucose \> 125 mg/dL, or any other lab test result(s) that would preclude participation in the study in the judgment of the PI/Sub-I
15. Having blood pressure readings at Baseline/screening \> 140 systolic or \> 90 diastolic on two consecutive readings unless permitted to proceed to the next visit in the judgment of the PI/Sub-I
16. Currently consumes more than 6 standard alcoholic drinks per week (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
17. History of known alcohol or substance abuse (e.g., opiates, benzodiazepines, or amphetamines)
18. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges and tangelos
19. Having any other significant circumstance that would preclude study participation in the judgment of the PI/Sub-I
2. History of allergy or sensitivity to any component of the study products
3. Donation of blood within 30 days prior Baseline/screening
4. Participation in another study within 30 days prior to Baseline/screening
5. Being pregnant, planning on becoming pregnant during study participation or breast feeding
6. Having the following medical condition(s): diabetes, hypotension, hypertension (changed antihypertensive medication or dose in the preceding 3 months and/or likely to do so during the study), cardiovascular disease (arrhythmia, edema with or without congestive heart failure, heart attack, stroke, abnormal EKG), gastrointestinal disease requiring daily prescribed medication (gastroesophageal reflux, gastritis, and peptic or duodenal ulcer), gallbladder disease or gallstones, biliary obstruction (past or present), endocrine disease (hyper- or hypothyroidism), psychiatric disorder (anxiety if untreated, eating disorder) neurologic disease (Parkinson's disease, intracranial hemorrhage, head injury, brain tumor, evidence of delirium, confusion, dementia, Alzheimer's disease, migraine headache (if last migraine headache was \< 3 years prior to Baseline/screening), urologic disease, chronic inflammatory or autoimmune disease, cancer (unless skin cancer other than melanoma which has been treated \> 3 years prior to Baseline/screening), liver and kidney disease, insomnia, blood coagulation disorder (anemia, thrombus, embolism), sleep apnea, or other condition(s) that would preclude participation in the study in the judgment of the investigator/sub-investigator (Sub-I).
7. Currently taking or having taken cholesterol-lowering medication(s) including HMGCR inhibitors, cholesterol binding resins, fibrates, or nicotinic acid \>1 gram/day within 30 days prior to screening
8. Currently taking or having taken a supplemental product that may affect cholesterol levels (red yeast rice, red mold dioscorea, guggulipid, policosanol, pantethine, beta-sitosterol, artichoke leaf, or supplemental fiber) within 30 days prior to Baseline/screening
9. Currently taking or having taken a fish oil or krill oil product within 30 days prior to Baseline/screening
10. Currently taking or having taken anxiolytics and sedative hypnotics, anticonvulsants, antineoplastics, anti-migraine medication(s), opioid analgesics, monoamine oxidase inhibitors (MAOIs), phosphodiesterase inhibitors, adenosine reuptake inhibitors, dopamine agonists, dopamine antagonists, or immunosuppressants within 30 days prior to Baseline/screening
11. Currently talking or having taken anti-inflammatory medication(s) within 14 days prior to screening (unless on a stable daily dose of aspirin 81mg for 3 months prior to screening and not likely to change dose during the study) or in the judgment of the PI/Sub-I would not preclude participation in the study
12. Having had a surgical procedure, pacemaker or any internal medical device other than artificial joints which, in the judgment of the PI/Sub-I, would preclude participation in the study
13. Having had a routine dental cleaning or other dental procedure within 14 days prior to Baseline/screening
14. Having screening laboratory test values: bilirubin \> 2.5 x ULN, AST/SGOT and ALT/SGPT \> 2.5 x ULN, serum creatinine \> 1.5 mg/dL, blood glucose \> 125 mg/dL, or any other lab test result(s) that would preclude participation in the study in the judgment of the PI/Sub-I
15. Having blood pressure readings at Baseline/screening \> 140 systolic or \> 90 diastolic on two consecutive readings unless permitted to proceed to the next visit in the judgment of the PI/Sub-I
16. Currently consumes more than 6 standard alcoholic drinks per week (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
17. History of known alcohol or substance abuse (e.g., opiates, benzodiazepines, or amphetamines)
18. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges and tangelos
19. Having any other significant circumstance that would preclude study participation in the judgment of the PI/Sub-I
Minimum Eligible Age
40 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Supplement Formulators, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Joyal, M.D.
Role: PRINCIPAL_INVESTIGATOR
Life Extension
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Life Extension Clinical Research, Inc.
Fort Lauderdale, Florida, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Ahmad S, Beg ZH. Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. Food Chem. 2013 Jun 1;138(2-3):1116-24. doi: 10.1016/j.foodchem.2012.11.109. Epub 2012 Dec 5.
Reference Type
BACKGROUND
Al-Naqeep G, Al-Zubairi AS, Ismail M, Amom ZH, Esa NM. Antiatherogenic Potential of Nigella sativa Seeds and Oil in Diet-Induced Hypercholesterolemia in Rabbits. Evid Based Complement Alternat Med. 2011;2011:213628. doi: 10.1093/ecam/neq071. Epub 2011 Jun 16.
Reference Type
BACKGROUND
Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003 Apr;17(4):299-305. doi: 10.1002/ptr.1309.
Reference Type
BACKGROUND
Amin F, Gilani AH, Mehmood MH, Siddiqui BS, Khatoon N. Coadministration of black seeds and turmeric shows enhanced efficacy in preventing metabolic syndrome in fructose-fed rats. J Cardiovasc Pharmacol. 2015 Feb;65(2):176-83. doi: 10.1097/FJC.0000000000000179.
Reference Type
BACKGROUND
Amin F, Islam N, Anila N, Gilani AH. Clinical efficacy of the co-administration of Turmeric and Black seeds (Kalongi) in metabolic syndrome - a double blind randomized controlled trial - TAK-MetS trial. Complement Ther Med. 2015 Apr;23(2):165-74. doi: 10.1016/j.ctim.2015.01.008. Epub 2015 Jan 14.
Reference Type
BACKGROUND
Asgary S, Sahebkar A, Goli-Malekabadi N. Ameliorative effects of Nigella sativa on dyslipidemia. J Endocrinol Invest. 2015 Oct;38(10):1039-46. doi: 10.1007/s40618-015-0337-0. Epub 2015 Jul 2.
Reference Type
BACKGROUND
Bamosa AO, Ali BA, al-Hawsawi ZA. The effect of thymoquinone on blood lipids in rats. Indian J Physiol Pharmacol. 2002 Apr;46(2):195-201.
Reference Type
BACKGROUND
Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011 Mar;4(3):354-64. doi: 10.1158/1940-6207.CAPR-10-0098.
Reference Type
BACKGROUND
Chen FY, Zhou J, Guo N, Ma WG, Huang X, Wang H, Yuan ZY. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun. 2015 Nov 27;467(4):872-8. doi: 10.1016/j.bbrc.2015.10.051. Epub 2015 Oct 19.
Reference Type
BACKGROUND
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul-Aug;21(4B):2895-900.
Reference Type
BACKGROUND
Dahri AH, Chandiol AM, Rahoo AA, Memon RA. Effect of Nigella sativa (kalonji) on serum cholesterol of albino rats. J Ayub Med Coll Abbottabad. 2005 Apr-Jun;17(2):72-4.
Reference Type
BACKGROUND
Dollah MA, Parhizkar S, Latiff LA, Bin Hassan MH. Toxicity effect of nigella sativa on the liver function of rats. Adv Pharm Bull. 2013;3(1):97-102. doi: 10.5681/apb.2013.016. Epub 2013 Feb 7.
Reference Type
BACKGROUND
Dong SZ, Zhao SP, Wu ZH, Yang J, Xie XZ, Yu BL, Nie S. Curcumin promotes cholesterol efflux from adipocytes related to PPARgamma-LXRalpha-ABCA1 passway. Mol Cell Biochem. 2011 Dec;358(1-2):281-5. doi: 10.1007/s11010-011-0978-z. Epub 2011 Jul 12.
Reference Type
BACKGROUND
Fan C, Wo X, Dou X, Xu L, Qian Y, Luo Y, Yan J. Regulation of LDL receptor expression by the effect of curcumin on sterol regulatory element pathway. Pharmacol Rep. 2006 Jul-Aug;58(4):577-81.
Reference Type
BACKGROUND
Haas MJ, Onstead-Haas LM, Naem E, Wong NC, Mooradian AD. Induction of apolipoprotein A-I gene expression by black seed (Nigella sativa) extracts. Pharm Biol. 2014 Sep;52(9):1119-27. doi: 10.3109/13880209.2013.879187. Epub 2014 Mar 17.
Reference Type
BACKGROUND
Heshmati J, Namazi N. Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: a systematic review. Complement Ther Med. 2015 Apr;23(2):275-82. doi: 10.1016/j.ctim.2015.01.013. Epub 2015 Feb 9.
Reference Type
BACKGROUND
Hosseinzadeh H, Parvardeh S, Asl MN, Sadeghnia HR, Ziaee T. Effect of thymoquinone and Nigella sativa seeds oil on lipid peroxidation level during global cerebral ischemia-reperfusion injury in rat hippocampus. Phytomedicine. 2007 Sep;14(9):621-7. doi: 10.1016/j.phymed.2006.12.005. Epub 2007 Feb 8.
Reference Type
BACKGROUND
Ibrahim RM, Hamdan NS, Ismail M, Saini SM, Abd Rashid SN, Abd Latiff L, Mahmud R. Protective Effects of Nigella sativa on Metabolic Syndrome in Menopausal Women. Adv Pharm Bull. 2014;4(1):29-33. doi: 10.5681/apb.2014.005. Epub 2013 Dec 23.
Reference Type
BACKGROUND
Kaatabi H, Bamosa AO, Lebda FM, Al Elq AH, Al-Sultan AI. Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients. J Family Community Med. 2012 Sep;19(3):155-61. doi: 10.4103/2230-8229.102311.
Reference Type
BACKGROUND
Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, Saengsuwan J, Tantayakom K, Laongpech S. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014 Mar 20;9:451-8. doi: 10.2147/CIA.S58535. eCollection 2014.
Reference Type
BACKGROUND
Lin XL, Liu MH, Hu HJ, Feng HR, Fan XJ, Zou WW, Pan YQ, Hu XM, Wang Z. Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXRalpha signaling in THP-1 macrophage-derived foam cells. DNA Cell Biol. 2015 Sep;34(9):561-72. doi: 10.1089/dna.2015.2866. Epub 2015 Jun 23.
Reference Type
BACKGROUND
Liu T, Li C, Sun H, Luo T, Tan Y, Tian D, Guo Z. Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage. Inflamm Res. 2014 Oct;63(10):841-50. doi: 10.1007/s00011-014-0758-9. Epub 2014 Jul 27.
Reference Type
BACKGROUND
Mirzabeigi P, Mohammadpour AH, Salarifar M, Gholami K, Mojtahedzadeh M, Javadi MR. The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial. Iran J Pharm Res. 2015 Spring;14(2):479-86.
Reference Type
BACKGROUND
Mooradian AD, Haas MJ. The effect of nutritional supplements on serum high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiovasc Drugs. 2014 Aug;14(4):253-74. doi: 10.1007/s40256-014-0068-1.
Reference Type
BACKGROUND
Morrone Mda S, Schnorr CE, Behr GA, Gasparotto J, Bortolin RC, da Boit Martinello K, Saldanha Henkin B, Rabello TK, Zanotto-Filho A, Gelain DP, Moreira JC. Curcumin Supplementation Decreases Intestinal Adiposity Accumulation, Serum Cholesterol Alterations, and Oxidative Stress in Ovariectomized Rats. Oxid Med Cell Longev. 2016;2016:5719291. doi: 10.1155/2016/5719291. Epub 2015 Nov 23.
Reference Type
BACKGROUND
Panahi Y, Hosseini MS, Khalili N, Naimi E, Soflaei SS, Majeed M, Sahebkar A. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition. 2016 Oct;32(10):1116-22. doi: 10.1016/j.nut.2016.03.018. Epub 2016 Mar 31.
Reference Type
BACKGROUND
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. J Cardiovasc Pharmacol. 2016 Sep;68(3):223-9. doi: 10.1097/FJC.0000000000000406.
Reference Type
BACKGROUND
Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem. 2007 Feb;18(2):113-9. doi: 10.1016/j.jnutbio.2006.03.007. Epub 2006 May 18.
Reference Type
BACKGROUND
Ragheb A, Elbarbry F, Prasad K, Mohamed A, Ahmed MS, Shoker A. Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. Int J Angiol. 2008 Winter;17(4):186-92. doi: 10.1055/s-0031-1278307.
Reference Type
BACKGROUND
Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, Goel A, Tripathi CB. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014 Apr;28(4):579-85. doi: 10.1002/ptr.5025. Epub 2013 Jul 6.
Reference Type
BACKGROUND
Sahebkar A, Beccuti G, Simental-Mendia LE, Nobili V, Bo S. Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016 Apr;106:37-50. doi: 10.1016/j.phrs.2016.02.008. Epub 2016 Feb 10.
Reference Type
BACKGROUND
Shafiq H, Ahmad A, Masud T, Kaleem M. Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. Iran J Basic Med Sci. 2014 Dec;17(12):967-79.
Reference Type
BACKGROUND
Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001 Jul;7(7):1894-900.
Reference Type
BACKGROUND
Shuid AN, Mohamed N, Mohamed IN, Othman F, Suhaimi F, Mohd Ramli ES, Muhammad N, Soelaiman IN. Nigella sativa: A Potential Antiosteoporotic Agent. Evid Based Complement Alternat Med. 2012;2012:696230. doi: 10.1155/2012/696230. Epub 2012 Sep 3.
Reference Type
BACKGROUND
Singh V, Jain M, Misra A, Khanna V, Rana M, Prakash P, Malasoni R, Dwivedi AK, Dikshit M, Barthwal MK. Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters. Br J Nutr. 2013 Aug 28;110(3):437-46. doi: 10.1017/S0007114512005363. Epub 2013 May 15.
Reference Type
BACKGROUND
Singh V, Rana M, Jain M, Singh N, Naqvi A, Malasoni R, Dwivedi AK, Dikshit M, Barthwal MK. Curcuma oil attenuates accelerated atherosclerosis and macrophage foam-cell formation by modulating genes involved in plaque stability, lipid homeostasis and inflammation. Br J Nutr. 2015 Jan 14;113(1):100-13. doi: 10.1017/S0007114514003195. Epub 2014 Nov 13.
Reference Type
BACKGROUND
Tai MH, Chen PK, Chen PY, Wu MJ, Ho CT, Yen JH. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res. 2014 Nov;58(11):2133-45. doi: 10.1002/mnfr.201400366. Epub 2014 Sep 19.
Reference Type
BACKGROUND
Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014 Dec;28(12):1770-7. doi: 10.1002/ptr.5197. Epub 2014 Aug 6.
Reference Type
BACKGROUND
Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of Nigella sativa fixed oil on blood homeostasis in rat. J Ethnopharmacol. 2002 Jan;79(1):23-6. doi: 10.1016/s0378-8741(01)00342-7.
Reference Type
BACKGROUND
Zhao JF, Ching LC, Huang YC, Chen CY, Chiang AN, Kou YR, Shyue SK, Lee TS. Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol Nutr Food Res. 2012 May;56(5):691-701. doi: 10.1002/mnfr.201100735.
Reference Type
BACKGROUND
Zingg JM, Hasan ST, Meydani M. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors. 2013 Jan-Feb;39(1):101-21. doi: 10.1002/biof.1072. Epub 2013 Jan 22.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL086
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Micellar Curcumin and Metabolic Syndrome Biomarkers
NCT01925547
COMPLETED
PHASE2
Effect of a Dietary Supplement on Lipid Pattern, Indexes of NAFLD and Systemic Inflammation in Healthy Subjects With Suboptimal LDL-C Levels
NCT06403748
NOT_YET_RECRUITING
NA
Effects of 8 Weeks of Turmeric Ingestion on Physiology and Wellbeing in Healthy Older Adults
NCT07196514
RECRUITING
NA
The Effects of Nanocurcumin on Serum Oxidative Stress,Inflammation,Adiponectin and NF-kB in Blood Mononuclear Cells in Metabolic Syndrome Patients (Nuclear Factor-κB)
NCT03514667
UNKNOWN
NA
A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)
NCT01152073
COMPLETED
NA
Effect of Dietary Intervention on LDL-C and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia
NCT04148976
COMPLETED
NA
Turmeric and Curcumin on Sebum Production
NCT03066791
COMPLETED
NA
Ginger and Plasma Cholesterol Efflux Capacity
NCT06662695
COMPLETED
NA
Comparison of Curcumin Bioavailability
NCT03530436
COMPLETED
NA
Pharmacokinetic Study on Three Formulations of Curcumin With Different Carriers
NCT04382014
UNKNOWN
NA
Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers
NCT03118583
COMPLETED
NA
A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury
NCT01634256
COMPLETED
PHASE2/PHASE3
Effect of Black Cumin Seed Oil Supplementation on Cortisol, Stress and Mood
NCT06950424
ACTIVE_NOT_RECRUITING
NA
Oral Bioavailability of Curcumin From Micronized Powder and Liquid Micelles in Healthy Young Women and Men
NCT01925287
COMPLETED
EARLY_PHASE1
Efficacy and Safety of Unripe Bokbunja Extract on Improvement of Blood Cholesterol
NCT03649620
COMPLETED
NA
Golden Black Seed: Support of Metabolic Health and General Wellness.
NCT03643094
COMPLETED
NA
Effects of Curcumin on Markers of Cardiovascular Risk in Patients With CAD
NCT04458116
WITHDRAWN
NA
Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects
NCT04760951
COMPLETED
NA
Comparing Effects of 3 Sources of Garlic on Cholesterol Levels
NCT00056511
COMPLETED
PHASE2/PHASE3
Investigations on the Effect of Kale on the Lipid Status
NCT03545555
UNKNOWN
NA
Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels
NCT03739242
COMPLETED
NA
Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
NCT02100202
UNKNOWN
NA
Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
NCT02203227
UNKNOWN
NA
Bioenhancing Effects of Black Pepper With Turmeric on Pain Ratings
NCT05206266
COMPLETED
NA